2025-10-05 - Analysis Report
Okay, here's an analysis of Hims & Hers Health Inc. (HIMS) based on the provided data, presented in a report format with key figures and concise analysis:

**Report: Hims & Hers Health Inc. (HIMS) Analysis**

**1. Company Overview**

Hims & Hers Health Inc. is a telehealth company offering personalized health and wellness solutions.

**2. Performance vs. S&P 500 (VOO)**

*   **HIMS Cumulative Return:** 244.52%
*   **VOO Cumulative Return:** 72.46%
*   **Absolute Deviation:** 207.0
*   **Relative Deviation:** 71.9 (Indicates HIMS's performance is in the upper range of its historical deviation from VOO.)

**Analysis:** HIMS has significantly outperformed the S&P 500. The relative deviation suggests that while the outperformance is substantial, it's within the historical range of HIMS's volatility compared to the market.

**3. Alpha, Beta Analysis**

| Year       | CAGR     | MDD   | Alpha  | Beta | Cap(B) |
|------------|----------|-------|--------|------|--------|
| 2019-2021  | -42.0%   | 74.4% | -81.0% | 0.0  | 1.5    |
| 2020-2022  | -19.0%   | 78.6% | -18.0% | -0.0 | 1.4    |
| 2021-2023  | -65.0%   | 78.6% | -67.0% | -0.1 | 2.0    |
| 2022-2024  | 119.0%  | 79.4% | 98.0%  | -0.0 | 5.5    |
| 2023-2025  | 249.0%  | 80.8% | 186.0% | 0.1  | 11.9   |

**Analysis:**

*   **CAGR:** Shows a strong positive trend in recent years, with significant growth in the 2023-2025 period.
*   **MDD:** High Maximum Drawdown indicates significant volatility.
*   **Alpha:** Positive alpha in the most recent period suggests HIMS is generating returns independent of the market.
*   **Beta:** Beta values are relatively low, indicating the stock is not strongly correlated with the market.
*   **Cap(B):** Market capitalization has increased significantly, reflecting company growth.

**4. Recent Price Action**

*   **Current Price:** $52.54
*   **Last-market:** `{'price': 52.54, 'previousClose': 57.87, 'change': -9.21}`
*   **5-day Moving Average:** 56.089
*   **20-day Moving Average:** 54.0122
*   **60-day Moving Average:** 51.7179

**Analysis:** The current price is below the 5-day and 20-day moving averages, but above the 60-day moving average, suggesting a potential short-term downtrend or consolidation after a recent price increase.  The significant negative change from the previous close indicates a sharp drop in price, warranting further investigation.

**5. Market Risk Indicators & Signals**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 47.62 (Neutral)
*   **PPO:** -0.14 (Slightly oversold)
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash
*   **Delta_Previous_Relative_Divergence:** 3.3 (+) (Short-term increase in relative outperformance)
*   **Expected Return:** 1.6% (Projected long-term outperformance vs. S&P 500)

**Analysis:**

*   The high MRI score suggests the market conditions are favorable for investment, but the recent price drop should be taken into consideration.
*   RSI is neutral, not indicating overbought or oversold conditions.
*   The PPO is slightly negative, which could suggest the asset is slightly oversold.
*   The positive change in relative divergence indicates some recent outperformance compared to the reference asset.
*   The hybrid signal recommends buying with available cash.

**6. Recent News & Significant Events**

*   **Why Hims & Hers Stock Slipped Today (Motley Fool):** Explains potential reasons for the recent price drop.
*   **Hims & Hers Expands Health Access Through Subscription Revenue Model (Zacks):** Highlights the company's growth strategy.
*   **Evaluating Hims & Hers Health (HIMS) Valuation After 39% Share Price Surge in the Past Month (Simply Wall St.):** Discusses the stock's valuation in light of recent gains.
*   **Breakout Stocks Watch: What Looms For October? (Investor's Business Daily):** Mentions HIMS as a potential breakout stock.
*   **agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know (StockStory):** Places HIMS in the context of other healthcare stocks.
*   **OMCL or HIMS: Which Is the Better Value Stock Right Now? (Zacks):** Compares HIMS to a competitor.

**Analysis:** Recent news indicates both positive and negative sentiment. The price drop is a concern, but expansion of the subscription model and recognition as a potential breakout stock are positive signs.

**7. Analyst Opinions**

*   **Mean Target Price:** $47.42
*   **Opinions:** 12
*   **Target Price Range:** $25.00 - $85.00

**Analysis:** The current price is slightly above the mean target price, suggesting analysts, on average, believe the stock is currently fairly valued, or slightly overvalued.  The wide range in target prices indicates uncertainty among analysts.

**8. Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-08-04 | 0.19 | 0.54 B$   |
| 2025-05-05 | 0.22 | 0.59 B$   |
| 2024-11-04 | 0.35 | 0.40 B$   |
| 2024-08-05 | 0.06 | 0.32 B$   |
| 2025-08-04 | 0.06 | 0.32 B$   |

**Analysis:** While revenue has generally increased, EPS has been volatile.  The most recent data point (2025-08-04) showing identical figures to 2024-08-05 may warrant further review for accuracy. The increase in revenue is a positive sign, but EPS needs to show consistent improvement.

**9. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.54B  | 76.39%        |
| 2025-03-31 | $0.59B  | 73.50%        |
| 2024-12-31 | $0.48B  | 76.81%        |
| 2024-09-30 | $0.40B  | 79.16%        |
| 2024-06-30 | $0.32B  | 81.30%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE    |
|------------|---------|--------|
| 2025-06-30 | $0.56B  | 7.55%  |
| 2025-03-31 | $0.55B  | 9.01%  |
| 2024-12-31 | $0.48B  | 5.46%  |
| 2024-09-30 | $0.44B  | 17.18% |
| 2024-06-30 | $0.36B  | 3.67%  |

**Analysis:** Revenue has shown strong growth, and profit margins remain high.  Equity has also increased, but ROE has been volatile. While profit margins are high, the decreasing trend might be a point of concern.

**10. Overall Assessment**

Hims & Hers Health Inc. demonstrates high growth potential, as evidenced by its substantial outperformance against the S&P 500 and increasing revenue. However, the company exhibits significant volatility, as indicated by the high MDD and recent price drop.

The market risk indicators suggest a favorable environment for investment, and the hybrid signal recommends buying. However, the recent negative price action, coupled with analyst target prices close to the current price, warrant caution.

**Recommendation:**

Given the mixed signals, a cautious approach is advised. The recent price decline and negative news headlines should be further investigated to understand the underlying causes. While the long-term growth potential remains attractive, potential investors should consider the stock's volatility and await further stabilization or positive catalysts before initiating a position. Existing investors might consider holding, but should closely monitor the company's performance and news flow. A dollar-cost averaging strategy might be appropriate to mitigate the risk of volatility.
